国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (4): 564-568.DOI: 10.3760/cma.j.issn.1007-1245.2023.04.028

• 临床研究 • 上一篇    下一篇

临床药师参与的用药管理对急性脑梗死介入术后患者用药规范性、用药依从性及安全性的影响

刘辉  王珍珍  赵亚非   

  1. 聊城市第三人民医院药剂科,聊城 252000

  • 收稿日期:2022-08-09 出版日期:2023-03-15 发布日期:2023-03-06
  • 通讯作者: 刘辉,Email:lcsylcyxlh@163.com

Effects of medication management with clinical pharmacists' participation on medication standardization, compliance, and safety in patients with acute cerebral infarction after intervention

Liu Hui, Wang Zhenzhen, Zhao Yafei   

  1. Department of Pharmacy, Liaocheng Third People's Hospital, Liaocheng 252000, China

  • Received:2022-08-09 Online:2023-03-15 Published:2023-03-06
  • Contact: Liu Hui, Email: lcsylcyxlh@163.com

摘要:

目的 探讨临床药师参与的用药管理对急性脑梗死介入术后患者用药规范性、用药依从性及安全性的影响。方法 选取20202月至20222月于聊城市第三人民医院接受介入术治疗的50例急性脑梗死患者进行随机对照试验,男性33例,女性17例,年龄(66.16±7.85)岁。采用随机数字表法将其分为对照组和观察组,各25例。对照组患者术后给予常规用药管理及健康宣教,观察组在以上基础给予临床药师参与的用药管理。记录两组合理用药指标(住院时间、住院费用、用药费用);干预前、干预3个月后对比两组用药规范性及用药依从性;评价安全性及满意度。采用t检验、方差分析和χ2检验。结果 观察组住院时间、住院费用、用药费用均低于对照组[(13.45±3.68d比(15.96±4.01d、(5 125.44±335.71)元比(5 543.75±340.94)元、(1 483.55±368.94)元比(1 876.43±377.56)元],差异均有统计学意义(t=2.3064.3713.721,均P<0.05)。干预后,观察组不合理用药发生率及用药依从性均优于对照组[16.00%4/25)比44.00%11/25)、96.00%24/25)比72.00%18/25)],差异均有统计学意义(均P<0.05)。观察组不良反应发生率低于对照组[12.00%3/25)比36.00%9/25)],且护理满意度高于对照组[96.00%24/25)比76.00%19/25)],差异均有统计学意义(χ2=3.9474.153,均P<0.05)。结论 临床药师参与的用药管理用于急性脑梗死介入术后,不仅能完善临床对患者的药物管理制度,改善用药效果,降低不合理用药的发生,还能提高患者用药依从性,减少不良反应对疾病康复的影响,且护理满意度较高。

关键词:

急性脑梗死, 临床药师参与的用药管理, 介入术, 用药规范性, 用药依从性, 安全性

Abstract:

Objective To investigate the effects of medication management with clinical pharmacists' participation on medication standardization, compliance, and safety in patients with acute cerebral infarction after intervention. Methods A total of 50 patients with acute cerebral infarction who underwent intervention in Liaocheng Third People's Hospital from February 2020 to February 2022 were selected for the random control trial, including 33 males and 17 females who were (66.16±7.85) years old. They were divided into a control group and an observation group by the random number table method, with 25 cases in each group. The control group received routine medication management and health education after operation; in addition, the observation group received medication management with clinical pharmacists' participation. The rational drug use indicators (hospital stay, hospitalization expense, and medication expense) were recorded. The medication standardization and medication compliances of the two groups were compared before and 3 months after the intervention. The safety and satisfaction were evaluated. t test, analysis of variance, and χ2 test were applied. Results The hospital stay, hospitalization expense, and medication expense of the observation group were lower than those of the control group [(13.45±3.68) d vs. (15.96±4.01) d, (5 125.44±335.71) yuan vs. (5 543.75±340.94) yuan, and (1 483.55±368.94) yuan vs. (1 876.43±377.56) yuan], with statistical differences (t=2.306, 4.371, and 3.721; all P<0.05). After the intervention, the incidence of irrational drug use and medication compliance rate in the observation group were better than those in the control group [16.00% (4/25) vs. 44.00% (11/25) and 96.00% (24/25) vs. 72.00% (18/25)], with statistical differences (both P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group [12.00 % (3/25) vs. 36.00 % (9/25)] and the nursing satisfaction in the observation group was higher than that in the control group [96.00 % (24/25) vs. 76.00 % (19/25)], with statistical differences (χ2=3.947 and 4.153; both P<0.05). Conclusion Medication management with clinical pharmacists' participation for patients with acute cerebral infarction after intervention can not only improve the clinical drug management system, enhance medication effect, and reduce irrational drug use, but also improve the patients' medication compliance and nursing satisfaction and reduce adverse reactions.

Key words:

Acute cerebral infarction, Medication management with clinical pharmacists' participation, Intervention, Medication standardization, Medication compliance, Safety